Skip to main content

Relation entre l’âge et les paramètres clinique et biologique. À propos de 67 cas d’hypertrophie bénigne de la prostate dans un hôpital ouest-algérien

Relationship between age and clinical and biological parameters. Sixtyseven cases of benign prostate hyperplasia in a western Algeria hospital

Résumé

Objectif

L’élévation sérique de l’antigène spécifique de la prostate (PSA) est révélatrice de pathologies prostatiques. L’âge, chez un homme, peut entraîner des fluctuations de concentration du PSA. L’objectif de cette étude est d’évaluer les relations entre l’âge et les paramètres clinique et biologique en cas d’hypertrophie bénigne de la prostate (HBP).

Matériel et méthodes

Un échantillon de 67 cas d’HBP, âgés de plus de 50 ans, a été diagnostiqué dans le service d’urologie de l’hôpital de Saïda entre 2007–2008. Les patients ont subi un dosage de PSA total (PSAT) alors que le PSA libre (PSAL) n’a été réalisé que chez 23,8 % des patients.

Résultats

L’âge moyen des patients était de 72,9 ans. Dans 82 % des cas, PSAT > 4 ng/ml dont 37,3 % avec un PSAT > 10 ng/ml. L’âge ne montre pas de corrélations avec le poids prostatique (PP) (r = 0,026, p > 0,05) et PSAT (r = − 0,036, p > 0,05) par contre il existe une corrélation significative entre PP et PSAT (r = 0,49, p < 0,01). Le ratio (PSAL / PSAT) moyen était de 54,23 % et plus de 40 % des patients avaient un PSAT entre 4–10 ng/ml dont 31 % avaient un ratio > 15 %.

Conclusion

Ces résultats suggèrent une éventuelle existence d’HBP pour des valeurs de PSAT entre 4–10 ng/ml associées à une augmentation du PP et un ratio supérieur à 15 %.

Abstract

Objective

Serum rising of prostate specific antigen (PSA) is revealing of prostate pathologies. Age may cause fluctuations of PSA concentration. The objective of this study is to assess the relations between the age, clinical and biological parameters in case of benign prostate hyperplasia (BPH).

Material and methods

A sample of 67 cases, aged over 50 years, was diagnosed in the urology service of Saïda hospital between 2007–2008. The patients underwent a total PSA (TPSA) serum assay whereas a free PSA (FPSA) was carried out only for 23.8% of patients.

Results

The average age was 72.9 years. TPSA was beyond 4 ng/ml for 82% of patients which 37,3% had TPSA higher than 10 ng/ml. The age doesn’t show correlation with prostatic weight (PW) (r = 0.026, p > 0.05) and TPSA (r = − 0.036, p > 0.05) but there is a significant correlation between PW and TPSA (r = 0.49, p < 0.01). The free fraction (FPSA/ TPSA) average was 54.23% and more than 40% of the patients had TPSA between 4–10 ng/ml whose 31%had a free fraction > 15%.

Conclusion

These results show the presence of BPH for TPSA values between 4–10 ng/ml associated with rising of the PW and a free fraction higher than 15%.

This is a preview of subscription content, access via your institution.

Références

  1. 1.

    Bo M, Ventura M, Marinello R, et al (2003) Relationship between prostatic specific antigen (PSA) and volume of the prostate in the benign hyperplasia in the elderly. Crit Rev Oncol Hematol 47:207–211

    PubMed  Article  Google Scholar 

  2. 2.

    Chautard D, Bocquillon V, Daver A, et al (2000) Est-il possible de définir un seuil de l’index de PSA libre utile en pratique urologique quotidienne ? Prog Urol 10:571–577

    PubMed  CAS  Google Scholar 

  3. 3.

    Janssen T, Schulman C (1994) Antigène prostatique spécifique: un bilan 15 ans après sa découverte. Prog Urol 4:171–180

    PubMed  CAS  Google Scholar 

  4. 4.

    Coussa L, Machuca S, Gauchez AS (2006) Le dépistage du cancer de la prostate en 2005: quelle place pour le PSA ? IBS 21:105–109

    Google Scholar 

  5. 5.

    Catalona WJ, Partin AW, Slawin KM, et al (1998) Use of the percentage of the free prostate-specific antigen to enhance the differenciation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Fulla Y, Noel M, Le Brun G (2008) Optimisation de l’utilisation du PSA. Médecine nucléaire 32:31–40

    Article  Google Scholar 

  7. 7.

    Rhodes T, Girman CJ, Jacobsen SJ, et al (1999) Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J urol 161:1174–1179

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Jakobsen H, Torp-pederson S, Juul N (1998) Ultrasonic evaluation of age-related human prostatic growth and development of benign prostatic hyperplasia. Scand J Urol Nephrol suppl. 107:26

    Google Scholar 

  9. 9.

    Roherborn CG, Boyle P, Gould L, Waldstreicher J (1998) Serum prostate specific antigen as predictor of prostate volume in men with benign prostate hyperplasia. Urol 53:581–589

    Article  Google Scholar 

  10. 10.

    Hammerer PG, McNeal JE, Stamey TA (1995) Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J urol 153:111–114

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907–923

    PubMed  CAS  Google Scholar 

  12. 12.

    Dalkin B, Ahmann F, Southwick P, Bottaccini M (1993) Derivation of normal prostate specific antigen (PSA) level by age. J Urol 149:413

    Google Scholar 

  13. 13.

    Rietbergen JBW, Kranse R, Hoedemaeker RF, et al (1998) Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study. Urology 52:237–246

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Bosch JLHR, Hop VJW, Bangma CH, et al (1995) Prostate specific antigen in a community-based of men without prostate cancer: correlation with prostate volume, age, body mass index and symptoms of prostatism. Prostate 27:241–249

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Kirillos MM (1996) Prostate-specific antigen and age. Is there a correlation? And why does it seem to vary? Eur Urol 30:296–301

    Google Scholar 

  16. 16.

    Densel A, May P (1991) Die Beeinflussung des PSA-Wertes durch benign Prostataerkrankungen. Urologe [B] 31:217

    Google Scholar 

  17. 17.

    Collins GN, Lee RJ, McKelvie GB, et al (1993) Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 71:455

    Google Scholar 

  18. 18.

    Heuzé-Vourc’h N, Courty Y (2001) Les formes circulantes du PSA. Immunoanal Biol Spéc 16:295–301

    Google Scholar 

  19. 19.

    Fong CJ, Sherwood ER, Braun EJ, et al (1992) Regulation of prostatic carcinoma cell proliferation and secretory activity by extracellular matrix and stromal secretions. Prostate 21:121

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Gambert SR (2001) Prostate cancer. When to offer screening in the primary care setting. Geriatrics 56:22–31

    PubMed  CAS  Google Scholar 

  21. 21.

    Harris RP, Lohr KN (2002) Screening for prostate cancer: an uptade of the evidence for the U.S. preventive services task force. Ann Int Med 137:917–929

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to A. Berroukche.

About this article

Cite this article

Berroukche, A., Bendahmane-Salmi, M. & Kandouci, A.B. Relation entre l’âge et les paramètres clinique et biologique. À propos de 67 cas d’hypertrophie bénigne de la prostate dans un hôpital ouest-algérien. J Afr Cancer 5, 198–203 (2013). https://doi.org/10.1007/s12558-013-0281-x

Download citation

Mots clés

  • PSA
  • Âge
  • Hypertrophie bénigne de la prostate
  • Poids prostatique

Keywords

  • PSA
  • Age
  • Prostate benign hyperplasia
  • Prostatic weight